麦克马斯特大学研究人员发现，GDF15激素除具有抑制食欲和促进体重下降的作用外，还能在不引起体重下降的情况下保护肝脏。1 该研究表明，GDF15通过激活脑-肝信号通路触发糖皮质激素释放，从而减少肝脏炎症并减缓肝脏疤痕发展。1 这一发现为代谢功能相关脂肪性肝炎（MASH）的治疗提供了新的治疗靶点。1
研究团队采用小鼠模型重现人类MASH，结合遗传学、药理学、基因组学和空间转录组学技术进行了检测。1 格里高利·斯坦伯格教授表示："GDF15激活了一条天然的脑-肝信号通路，帮助抑制肝脏炎症和减少纤维化"。1 该研究发表于2026年8月10日的《细胞代谢》杂志，研究资金来自加拿大自然科学与工程研究委员会（NSERC）、加拿大健康研究院（CIHR）和加拿大糖尿病协会。1
Researchers at McMaster University have identified a protective mechanism of GDF15, a hormone known for its appetite-suppressing and weight-reducing properties, that operates through a distinct biological pathway.1 The hormone activates a natural brain-liver signaling pathway that triggers glucocorticoid release, thereby shielding the liver from inflammation and fibrosis even when weight loss does not occur.1 According to Professor Gregory Steinberg, "GDF15 activates a natural brain-liver signaling pathway that helps suppress liver inflammation and reduce fibrosis."1
The findings, published in Cell Metabolism on August 10, 2026, offer a new therapeutic target for metabolic dysfunction-associated fatty liver disease (MASH).1 The team employed mouse models that recapitulated human MASH, employing genetics, pharmacology, genomics, and spatial transcriptomics to detect the hormone's effects.1 The research was supported by funding from the Natural Sciences and Engineering Research Council of Canada (NSERC), the Canadian Institutes of Health Research (CIHR), and the Canadian Diabetes Association.1
评论
还没有评论，欢迎留下第一条。